Cargando…
The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797650/ https://www.ncbi.nlm.nih.gov/pubmed/35117071 http://dx.doi.org/10.21037/tcr.2018.10.17 |
| _version_ | 1784641602774368256 |
|---|---|
| author | Roviello, Giandomenico Generali, Daniele Sobhani, Navid |
| author_facet | Roviello, Giandomenico Generali, Daniele Sobhani, Navid |
| author_sort | Roviello, Giandomenico |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8797650 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87976502022-02-02 The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study Roviello, Giandomenico Generali, Daniele Sobhani, Navid Transl Cancer Res Editorial AME Publishing Company 2019-03 /pmc/articles/PMC8797650/ /pubmed/35117071 http://dx.doi.org/10.21037/tcr.2018.10.17 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
| spellingShingle | Editorial Roviello, Giandomenico Generali, Daniele Sobhani, Navid The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study |
| title | The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study |
| title_full | The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study |
| title_fullStr | The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study |
| title_full_unstemmed | The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study |
| title_short | The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study |
| title_sort | combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of her2-negative breast cancer—a commentary on the e5103 randomized phase iii clinical study |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797650/ https://www.ncbi.nlm.nih.gov/pubmed/35117071 http://dx.doi.org/10.21037/tcr.2018.10.17 |
| work_keys_str_mv | AT roviellogiandomenico thecombinationofbevacizumabwithchemotherapyismorebeneficialinthemetastaticsettingratherthanintheadjuvantsettingforthetreatmentofher2negativebreastcanceracommentaryonthee5103randomizedphaseiiiclinicalstudy AT generalidaniele thecombinationofbevacizumabwithchemotherapyismorebeneficialinthemetastaticsettingratherthanintheadjuvantsettingforthetreatmentofher2negativebreastcanceracommentaryonthee5103randomizedphaseiiiclinicalstudy AT sobhaninavid thecombinationofbevacizumabwithchemotherapyismorebeneficialinthemetastaticsettingratherthanintheadjuvantsettingforthetreatmentofher2negativebreastcanceracommentaryonthee5103randomizedphaseiiiclinicalstudy AT roviellogiandomenico combinationofbevacizumabwithchemotherapyismorebeneficialinthemetastaticsettingratherthanintheadjuvantsettingforthetreatmentofher2negativebreastcanceracommentaryonthee5103randomizedphaseiiiclinicalstudy AT generalidaniele combinationofbevacizumabwithchemotherapyismorebeneficialinthemetastaticsettingratherthanintheadjuvantsettingforthetreatmentofher2negativebreastcanceracommentaryonthee5103randomizedphaseiiiclinicalstudy AT sobhaninavid combinationofbevacizumabwithchemotherapyismorebeneficialinthemetastaticsettingratherthanintheadjuvantsettingforthetreatmentofher2negativebreastcanceracommentaryonthee5103randomizedphaseiiiclinicalstudy |